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Summary Key Points 
 Seasonal influenza activity in the United States remained high in this week’s 
FluView report.  
 This week, 48 states are still reporting widespread geographic influenza activity. 
Oregon is reporting regional activity. Hawaii is now reporting local activity (down 
from regional last week). 
 The proportion of people seeing their health care provider for influenza-like-illness 
(ILI) remained stable.  
o Note: With backfilled ILI data, ILI for week 5 is 7.5% (down from 7.7% 
reported last week), and remains at 7.5% for week 6.  
 These are the highest levels of ILI recorded since the 2009 H1N1 pandemic, which 
peaked at 7.7% ILI. 
 Forty-three states, the District of Columbia, New York City and Puerto Rico 
experienced high ILI activity. (This is the same as was reported last week). 
 This is the 12th week that ILI has been at or above the national baseline.  
 By this measure, the past five seasons have averaged 16 weeks, with the longest 
season lasting 20 weeks.  
 It’s likely there will be significant flu activity for many weeks to come. 
 Flu activity indicators are notable for the sheer volume and intensity of flu that is 
occurring in most of the country at the same time.  
 While H3N2 viruses continue to be predominant this season, the overall proportion 
of influenza A viruses is declining and the proportion of influenza B viruses is 
increasing. H1N1 viruses are also increasing in number though not as much as B 
viruses. 
 There is usually co-circulation of influenza viruses during any one season and it’s 
not uncommon for there to be second waves of influenza B activity during an 
influenza season also. 
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 In past seasons similar to this one, an estimated 34 million Americans have gotten 
sick with flu. 
 The cumulative hospitalization rate (for week 6) is 67.9/100,000, which is higher 
than was seen for this same week during the 2014-2015 season (52.9) and is 
higher than the end-of-season cumulative rate of 64.2/100,000.  
 2014-2015 season was a high severity, H3N2-predominant season. 
 The highest hospitalization rate is among people 65 and older at 294.9/100,000. 
This rate is higher than what was reported for the same week of 2014-2015 
(262.1/100,000) and approaching the final cumulative rate of 308.8 per 100,000 
that season. 
 The next highest rate is among people 50 to 64 years of age. At 72.8/100,000, this 
rate is higher than both the week 6 report of 41.7 and the cumulative end-of-
season rate of 53.4/100,000 for the 2014-2015 season.  
 The next highest rate is among children 0-4 years. At 47.1/100,000, their 
hospitalization rate is slightly higher than the 45.3/100,000 rate reported during 
week 6 of 2014-2015 but still lower than the cumulative end of season rate of 
57.3/100,000. 
 So for people 50 years and older, this is turning out to be a more severe season 
than 2014-2015 in terms of hospitalizations. We still need to wait to see whether it 
is also more severe for children. 
 It seems that the rate of increase in hospitalizations is slowing. 
 However, it is possible that the number of flu hospitalizations may exceed 710,000, 
which is the high end of the estimated number of hospitalizations that have 
occurred in the United States since 2010. 
 The proportion of deaths attributed to pneumonia and influenza (P & I) is down 
slightly this week to 9.8% but remains above the epidemic threshold, which means 
that more deaths are occurring due to pneumonia and influenza that would be 
expected at this time. 
 P & I has been above the epidemic threshold for 6 weeks. 
 An additional 22 flu-related pediatric deaths were reported this week, bringing the 
total number of flu-related pediatric deaths reported to CDC so far to 84. 
 This is the highest number of pediatric deaths ever reported during a single week of 
a regular flu season since pediatric deaths became nationally notifiable in 2004. 
 Previously, the highest number of pediatric deaths reported during one week was 
19 deaths during the 2014-2015 season.  
 Early, interim influenza vaccine effectiveness (VE) for this season were published on 
Thursday. 
 Overall VE was 36%. That means a vaccinated person’s risk of having to go to the 
doctor because of flu was reduced by more than one-third. 
 Effectiveness was 25% against H3N2, 67% against H1N1 and 42% against 
influenza B viruses.  
 These findings are similar to what has been observed in the past. 
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 A study that looked at a number of VE estimates from 2004-2015 found 
average VE of 33% (CI = 26%–39%) against H3N2 viruses, compared with 
61% (CI = 57%–65%) against H1N1 and 54% (CI = 46%–61%) against 
influenza B viruses. 
 It is noteworthy that VE against H3N2 among children 6 months to 8 years old was 
51%. 
 The relatively lower vaccine effectiveness seen against H3N2 viruses may, in part, 
be caused by egg-adapted changes introduced when H3N2 viruses are optimized for 
growth in eggs, which is required for the egg-based production used to produce 
most U.S. flu vaccines.  
 Other factors may be playing a role in reduced VE against H3N2 this season, 
including host factors. (See U.S. VE key points). 
 CDC recommends a 3-pronged strategy to fight flu. 1. Take time to get a flu 
vaccine. 2, Take everyday preventive actions, including staying away from sick 
people, and 3, Take antiviral drugs if your doctor prescribes them. 
 As long as flu viruses are circulating, vaccination should continue throughout the flu 
season, even in January. 
 There are many reasons to get a flu vaccine. 
1. While flu vaccine can vary in how well it works, it is the best way to prevent 
flu illness and serious flu complications, including those that can result in 
hospitalization. 
2. We cannot know which viruses will circulate over the season and which virus 
will predominate. Flu vaccine protects against three or four different flu 
viruses, depending on which vaccine you get.  
3. A 2017 study was the first of its kind to show that flu vaccination can 
significantly reduce a child’s risk of dying from influenza. 
4. Getting vaccinated yourself protects people around you, including those who 
are more vulnerable to serious flu illness, like babies and young children, 
older people, and people with certain chronic health conditions. 
5. While flu vaccine is not perfect and some people who get vaccinated may still 
get flu, there is some data to suggest that flu vaccination may make illness 
milder. 
 While flu vaccine is the best way to prevent flu, influenza antiviral drugs are a 
second line of defense that can be used to treat flu illness. 
 Most people who are otherwise healthy and get the flu do not need to be treated 
with antiviral drugs, but some people are more likely to get very sick, especially the 
very young, the very old, pregnant women, and those with medical conditions that 
put them at high risk for developing severe infection. 
 CDC recommends prompt treatment with flu antiviral drugs for people who are very 
sick with flu symptoms or people who are at high risk of developing serious flu 
complications when they get flu symptoms. 
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 The volume of flu the country is experiencing right now has led to spot shortages of 
flu vaccine, antiviral drugs and even tests to quickly diagnose flu. 
 People may need to be persistent to locate vaccine, antiviral drugs to fill a 
prescription. 
Key Flu Indicators 
Influenza activity remains elevated according to the latest FluView report. All U.S. states 
but Hawaii and Oregon continue to report widespread flu activity and 43 states plus New 
York City, the District of Columbia and Puerto Rico continue to report high influenza-like 
illness (ILI) activity. The overall hospitalization rate is higher than the overall 
hospitalization rate reported for the same week of 2014-2015; a high severity, H3N2-
predominant season. CDC also is reporting an additional 22 flu-related pediatric deaths 
during week 6, bringing the total number of flu-related pediatric deaths reported this 
season to 84. Among reported pediatric flu deaths this season, only 26% of children 
eligible for vaccination had received any flu vaccine this season before they got sick. Flu 
activity is likely to remain elevated for several more weeks.  
 
CDC continues to recommend influenza vaccination for all persons 6 months of age and 
older as flu viruses are likely to continue circulating for weeks and there is an increasing 
proportion of influenza B and H1N1 viruses being detected. Early estimates show that flu 
vaccine has reduced risk of having to go to the doctor due to flu by 36% overall so far this 
season and that flu vaccine is offering substantial protection against H1N1 flu as well as 
moderate protection against flu B viruses. In addition, in the context of widespread 
influenza activity, CDC is reminding clinicians and the public about the importance of 
prompt treatment with antiviral medications in people who are severely ill and people who 
are at high risk of serious flu complications who develop flu symptoms. Below is a 
summary of the key flu indicators for the week ending February 10, 2018 (week 6): 
 
 Influenza-like Illness Surveillance: For the week ending February 10, the 
proportion of people seeing their health care provider for influenza-like illness (ILI) 
was 7.5%, which is above the national baseline of 2.2%. Last week (week 5), ILI 
was reported to have reached 7.7%, the same as the peak of the 2009 H1N1 
pandemic, however, additional data submitted for week 5 subsequently has 
resulted in the week 5 ILI being recalculated at 7.5%. All 10 regions reported a 
proportion of outpatient visits for ILI at or above their region-specific baseline 
levels. ILI has been at or above the national baseline for 12 weeks so far this 
season. Over the past five seasons, ILI has remained at or above baseline for 16 
weeks on average. 
 
o Additional ILINet data, including national, regional, and select state-level 
data for the current and previous seasons, can be found at 
http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. 
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 Influenza-like Illness State Activity Indicator Map: New York City, the District 
of Columbia, Puerto Rico and 43 states experienced high ILI activity (Alabama, 
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, 
Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, 
Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New 
Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, 
Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, 
Texas, Vermont, Virginia, West Virginia, Wisconsin, and Wyoming). Two states 
(North Dakota and Utah) experienced moderate ILI activity. Three states 
experienced low ILI activity (Hawaii, Idaho, and Washington). Two states 
experienced minimal ILI activity (Maine and Montana).  
 
o Additional data, including data for previous seasons, can be found at 
https://gis.cdc.gov/grasp/fluview/main.html  
 Geographic Spread of Influenza Viruses: Widespread influenza activity was 
reported by Puerto Rico and 48 states (Alabama, Alaska, Arizona, Arkansas, 
California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, 
Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, 
Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New 
Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, 
Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, 
Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, 
and Wyoming). Regional influenza activity was reported by Oregon. Local influenza 
activity was reported by the District of Columbia, Guam and one state (Hawaii). No 
flu activity was reported by the U.S. Virgin Islands. Geographic spread data show 
how many areas within a state or territory are seeing flu activity. 
 
o Additional data are available at: 
https://gis.cdc.gov/grasp/fluview/FluView8.html.   
 Flu-Associated Hospitalizations: Since October 1, 2017, 19,398 laboratory-
confirmed influenza-associated hospitalizations have been reported through the 
Influenza Hospitalization Network (FluSurv-NET), a population-based surveillance 
network for laboratory-confirmed influenza-associated hospitalizations. This 
translates to a cumulative overall rate of 67.9 hospitalizations per 100,000 people 
in the United States.  
o The highest hospitalization rate is among people 65 years and older (294.9 
per 100,000), followed by adults aged 50-64 years (72.8 per 100,000), and 
younger children aged 0-4 years (47.1 per 100,000). During most seasons, 
adults 65 years and older have the highest hospitalization rates, followed by 
children 0-4 years.  
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o During the 2014-2015 season, the cumulative overall hospitalization rate 
reported during week 6 was 48.6 per 100,000. During that same week, 
hospitalization rates for people 65 years and older were 242.2 per 100,000. 
Hospitalization rates for younger children 0-4 years were 43.4 per 100,000. 
o Hospitalization data are collected from 13 states and represent approximately 
9% of the total U.S. population. The number of hospitalizations reported 
does not reflect the actual total number of influenza-associated 
hospitalizations in the United States. Additional data, including hospitalization 
rates during other influenza seasons, can be found at 
http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html and 
http://gis.cdc.gov/grasp/fluview/FluHospChars.html.  
 
 Mortality Surveillance:  
o The proportion of deaths attributed to pneumonia and influenza (P&I) is high 
again at 9.8% for the week ending January 27, 2018 (week 4). This 
percentage is above the epidemic threshold of 7.3% for week 4 in the 
National Center for Health Statistics (NCHS) Mortality Surveillance System.  
o Region and state-specific data are available at 
https://gis.cdc.gov/grasp/fluview/mortality.html.    
 Pediatric Deaths 
o 22 influenza-associated pediatric deaths were reported to CDC during week 
6. 
 Four deaths were associated with an influenza A(H3) virus and occurred 
during weeks 2, 4, and 5 (the weeks ending January 13, January 27, and 
February 3, 2018, respectively).  Five deaths were associated with an 
influenza A(H1N1)pdm09 virus and occurred during weeks 52, 5, and 6 
(the weeks ending December 30, 2017, February 3, and February 10, 
2018, respectively).  Eight deaths were associated with an influenza A 
virus for which no subtyping was performed and occurred during weeks 
51, 2, 3, 5, and 6 (the weeks ending December 23, 2017, January 13, 
January 20, February 3, and February 10, 2018, respectively).  Five 
deaths were associated with an influenza B virus and occurred during 
weeks 2, 5 and 6 (the weeks ending January 13, February 3, and 
February 10, 2018, respectively).    
 One death that was reported earlier this season was reclassified by the 
reporting jurisdiction.  
o A total of 84 influenza-associated pediatric deaths for the 2017-2018 flu season 
have been reported to CDC. 
o Additional information on pediatric deaths is available on FluView Interactive 
at: https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html.   
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 Laboratory Data:  
o Nationally, the percentage of respiratory specimens testing positive for 
influenza viruses in clinical laboratories during the week ending February 10 
was 26.5%. 
o Regionally, the three-week average percent of specimens testing positive for 
influenza in clinical laboratories ranged from 15.0% to 31.4%. 
o During the week ending February 10, of the 17,040 (26.5%) influenza-
positive tests reported to CDC by clinical laboratories, 10,837 (63.6%) were 
influenza A viruses and 6,203 (36.4%) were influenza B viruses. 
o The most frequently identified influenza virus subtype reported by public 
health laboratories was influenza A(H3N2) virus.   
o During the week ending February 10, 1,109 (66.2%) of the 1,676 influenza-
positive tests reported to CDC by public health laboratories were influenza A 
viruses and 567 (33.8%) were influenza B viruses. Of the 1,071 influenza A 
viruses that were subtyped, 870 (81.2%) were H3N2 viruses and 201 
(18.8%) were (H1N1)pdm09 viruses. 
o The majority of the influenza viruses collected from the United States during 
October 1, 2017 through February 10, 2018 were characterized antigenically 
and genetically as being similar to the cell-grown reference viruses 
representing the 2017–18 Northern Hemisphere influenza vaccine viruses. 
o Since October 1, 2017, CDC has tested 431 influenza A(H1N1)pdm09, 962 
influenza A(H3N2), and 418 influenza B viruses for resistance to antiviral 
medications (i.e. oseltamivir, zanamivir, or peramivir). While the majority of 
the tested viruses showed susceptibility to the antiviral drugs, four (0.9%) 
H1N1pdm09 viruses were resistant to both oseltamivir and peramivir, but 
was sensitive to zanamivir. 
FluView (http://www.cdc.gov/flu/weekly/fluactivitysurv.htm) is available – and past 
issues are archived (http://www.cdc.gov/flu/weekly/pastreports.htm) – on the CDC 
website. 
Note: Delays in reporting may mean that data changes over time. The most up to 
date data for all weeks during the 2017-2018 season can be found on the current 
FluView(http://www.cdc.gov/flu/weekly/) and FluView Interactive 
(https://www.cdc.gov/flu/weekly/fluviewinteractive.htm). 
Pediatric Deaths 
 Twenty-two influenza-associated pediatric deaths were reported to CDC during 
week 6 of the 2017-2018 season.  
 Four deaths were associated with an influenza A(H3) virus and occurred during 
weeks 2, 4, and 5 (the weeks ending January 13, January 27, and February 3, 
2018, respectively).  Five deaths were associated with an influenza A(H1N1)pdm09 
virus and occurred during weeks 52, 5, and 6 (the weeks ending December 30, 
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2017, February 3, and February 10, 2018, respectively).  Eight deaths were 
associated with an influenza A virus for which no subtyping was performed and 
occurred during weeks 51, 2, 3, 5, and 6 (the weeks ending December 23, 2017, 
January 13, January 20, February 3, and February 10, 2018, respectively).  Five 
deaths were associated with an influenza B virus and occurred during weeks 2, 5 
and 6 (the weeks ending January 13, February 3, and February 10, 2018, 
respectively).  A total of 84 influenza-associated pediatric deaths have been 
reported for the 2017-2018 season. 
 Since 2004, when pediatric deaths associated with influenza infection became 
nationally notifiable, the number of deaths reported to CDC each year has ranged 
from 37 (2011-2012 season) to 171 deaths (2012-2013 season). 
 Last season, 2016-2017, 110 influenza-associated pediatric deaths were reported 
to CDC. 
 During past seasons, approximately 80% of flu-associated deaths in children have 
occurred in children who were not vaccinated. This proportion is similar for 2017-
2018 season (74% as of week 5).  
 Since the 2010-2011, between 43.8% to 59% of pediatric deaths occurred in 
children who were otherwise healthy and didn’t have an underlying medical 
condition. 
 Because of confidentiality issues, CDC does not discuss or give details on 
individuals. 
 These deaths are a somber reminder of the danger flu poses to children. 
 The single best way to protect against seasonal flu and its potentially severe 
consequences in children is to get a seasonal flu vaccine each year. 
 Vaccination is important for children younger than 5 years. It is especially 
important for those younger than 2 years and children of any age with a long-term 
health condition like asthma, diabetes and heart disease and neurological and 
neurodevelopmental diseases. These children are at higher risk of serious flu 
complications if they get the flu. 
 Yearly vaccination also is especially important for people in contact with high risk 
children in order to protect the child (or children) in their lives from the flu. In 
particular, children younger than 6 months are too young to be vaccinated 
themselves but are at high risk of flu complications if they get sick so the people 
around them should get vaccinated to protect the infant. 
 Some children 6 months through 8 years of age require 2 doses of influenza 
vaccine. Children in this age group who are getting vaccinated for the first time will 
need two doses. Some children who have received influenza vaccine previously also 
will need two doses this season. A health care provider should be consulted to 
determine whether two doses are recommended for a child. 
 Flu-associated deaths in children younger than 18 years old should be reported 
through the Influenza-Associated Pediatric Mortality Surveillance System. The 
number of flu-associated deaths among children reported during the 2017-2018 flu 
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season will be updated each week and can be found at www.cdc.gov/flu/weekly/ 
and https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html. 
 
U.S. Flu Vaccine Effectiveness Estimates 
Topline Messages 
 On February 15, CDC published a Morbidity and Mortality Weekly Report (MMWR) 
entitled “Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness – 
United States, February 2018.” This report is available online at 
https://www.cdc.gov/mmwr/index.html . 
 During each flu season since 2004-2005, CDC has estimated the effectiveness of 
seasonal flu vaccines to prevent laboratory-confirmed flu illness resulting in a 
doctor’s visit.*  
*Clinically what is being measured is laboratory confirmed influenza 
associated with medically attended acute respiratory illness (ARI).  
 This report uses data from 4,562 children and adults enrolled in the U.S. Influenza 
Vaccine Effectiveness Network (U.S. Flu VE Network) during November 2, 2017 – 
February 3, 2018.  
 During this period, overall adjusted vaccine effectiveness (VE) against influenza A 
and B virus infection was 36% (95% CI: 27% to 44%).  
 This means that CDC’s early 2017-2018 estimates show the flu vaccine has 
performed similarly to what CDC expected at the beginning of the season with 
A(H3N2) viruses driving the majority of flu activity. Overall, the seasonal flu vaccine 
has reduced the risk of getting sick and having to go to the doctor from flu by about 
one third. 
 Influenza A(H3N2) viruses were responsible for most (69%) of the flu infections 
reported in this study, and as expected, VE was lower against influenza A(H3N2) 
viruses.  
 VE was 25% (95% CI: 13%–36%) against illness caused specifically by influenza 
A(H3N2) viruses. 
 Of note: VE was much higher in children 6 months through 8 years of age: overall 
VE against influenza A and B viruses was 59% (95% CI: 44%–69%) in this age 
group.  
 Children in this age group also had higher VE specifically against A(H3N2). VE 
against A(H3N2) viruses was 51% (95% CI: 29%—66%) in children 6 months 
through 8 years of age. This means the risk for A(H3N2) illness that required a 
doctor’s visit was reduced by more than half among this group of vaccinated 
children. 
 VE against other flu viruses, including against influenza A(H1N1) and influenza B 
viruses, also was higher than against A(H3N2). 
o VE was 67% (CI:54%–76%) against influenza A(H1N1)pdm09 viruses 
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o VE was 42% (CI: 25%–56%) against influenza B viruses, providing a 
moderate level of protection.  
 These interim VE estimates reflect the ongoing challenges with creating effective flu 
vaccines against influenza A(H3N2) viruses. (H3N2 viruses have proven problematic 
since the 2011–12 season.) 
 The interim estimate of 25% VE against A(H3N2) viruses this season shows that 
seasonal flu vaccines are providing some protection, in contrast to recently 
reported, non-significant interim estimates of 17% from Canada and 10% from 
Australia.  
 These results also are similar to the final U.S. VE estimates of 32% against 
A(H3N2) viruses reported last season (2016-2017). 
 However, there is room for improvement. 
 There are many possible reasons for lower effectiveness against H3N2 viruses, and 
it’s important to get more data to help develop better flu vaccines.  
 Several hypotheses for why flu vaccines provide less benefit against H3N2 viruses 
could include the following: 
o Host factors, such as how a person’s unique immune system responds to 
vaccination or previous flu infections.  
 Note: some existing science suggests that the flu viruses people are 
exposed to early in life will affect the way their immune systems 
respond to flu infection or vaccination later in life – a process called 
“imprinting” or “original antigenic sin.”   
o Another factor could be the unique characteristics of circulating H3N2 viruses 
and changes that occur in H3N2 viruses over time.  
o And lastly, the egg-adapted changes that occur with greater frequency in 
H3N2 viruses when they are grown in eggs as part of the flu vaccine 
manufacturing process. Note: A(H3N2) viruses are particularly difficult to 
grow in eggs. 
 While these points represent factors that public health scientists and officials must 
study and better understand in the future, these early VE estimates also underscore 
the need for ongoing influenza prevention and treatment measures now. 
 CDC continues to recommend flu vaccination because the flu vaccine can still 
prevent some infections with flu viruses that are expected to continue circulating 
for several weeks. 
o Vaccine effectiveness point estimates for influenza B and A (H1N1) indicate 
that 2017-2018 flu vaccines will reduce people’s risk of flu illness associated 
with influenza B or A(H1N1) viruses that results in a doctor’s visit by 42% to 
67%.  
o Also, even with vaccine effectiveness of 25% against H3N2 viruses, flu 
vaccination will still prevent a substantial amount of illness due to this virus.  
o Flu vaccination has prevented thousands of hospitalizations during previous 
seasons when A(H3N2) viruses were predominant, including during the 
CDC Influenza Division Key Points          
February 16, 2018 
11 
 
2014–15 season when interim VE estimates were similar to those reported 
here. 
 In the United States, annual vaccination against seasonal flu is recommended for all 
people 6 months of age and older.  
 In addition, appropriate use of flu antiviral medications for treatment of severely ill 
people or people at high risk for complications from the flu who develop flu 
symptoms is important, especially among older adults, who currently have the 
highest hospitalization rates. 
 The VE estimates being reported today are interim estimates for the 2017-2018 
season, and the final VE estimates will be published after the season is over. The 
final season VE estimates may differ from these interim estimates, and based on 
previous end of season estimates, they may be a little lower than the interim 
estimates.  
 CDC will continue to monitor vaccine effectiveness through the rest of the season. 
Yearly monitoring of vaccine effectiveness is critical to identifying vaccine issues 
that need to be understood and corrected.  
Methods 
 At five study sites, patients 6 months of age and older seeking outpatient medical 
care for ARI with cough within 7 days of illness onset were enrolled. The five study 
sites of the U.S. Flu VE Network are located in the following states: 
o Wisconsin, 
o Michigan, 
o Washington 
o Pennsylvania, and  
o Texas. 
 Participants were interviewed to collect demographic data, information on general 
and current health status, and symptoms, and 2017-2018 vaccination status.  
o (Note: a limitation of this current data is that vaccination status included 
self-report at four of five sites. Self-reporting can bias results towards higher 
vaccination rates.) 
 Nasal and oropharyngeal swabs (or nasal swabs) were collected to obtain 
respiratory specimens.  
 Specimens were tested at U.S. Flu VE Network laboratories using CDC’s rRT-PCR 
protocol. 
 VE against all influenza virus types combined and against viruses by type/subtype 
were estimated as 100% x (1 – odds ratio). 
 Estimates were adjusted for study site, age group, sex, race/ethnicity, self-rated 
general health, number of days from illness onset to enrollment, and week of 
illness. 
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 Interim VE estimates for the 2017-18 season were based on patients enrolled 
through February 3, 2018. 
Results 
 Among the 4,562 children and adults with ARI enrolled at the five study sites from 
November 2, 2017 through February 3, 2018, a total of 1,712 (38%) tested 
positive for influenza by rRT-PCR, including 1,392 (81%) influenza A viruses and 
323 (19%) influenza B viruses. 
 Among 1,340 subtyped influenza A viruses, 1,143 (85%) were A/(H3N2) viruses 
and 208 (16%) were A(H1N1)pdm09 viruses. 
 Most (98%) of influenza B viruses belonged to the B/Yamagata lineage. 
 The proportion of patients with influenza differed by study site, sex, age group, 
race/ethnicity, self-rated health status, and interval from illness onset to 
enrollment.  
 The percentage of patients who were vaccinated ranged from 45% to 59% among 
study sites and differed by sex, age group, race/ethnicity, and self-rated health 
status. 
 Among ARI patient participants, 43% of those with influenza had received the 
2017-2018 seasonal influenza vaccine, compared with 53% of influenza –negative 
participants. 
 VE During this period, overall adjusted vaccine effectiveness (VE) against influenza 
A and B virus infection associated with medically attended ARI was 36% (95% CI: 
27% to 44%).  
o Most (69%) of influenza infections were caused by influenza A(H3N2) 
viruses.  
o VE was estimated to be 25% (95% CI: 13%–36%) against illness caused by 
influenza A(H3N2) viruses 
o Of note: statistically significant protection against medically attended 
influenza was found among children 6 months through 8 years of age: VE 
was 59% (95% CI: 44%–69%). 
o VE was estimated to be 67% (CI:54%–76%) against A(H1N1)pdm09 viruses  
o VE was estimated to be 42% (CI: 25%–56%) against influenza B viruses. 
 As of February 3, 2018, a total of 257 influenza A(H3N2) viruses from U.S. Flu VE 
Network participants had been characterized by CDC.  
o 240 (93%) belonged to either genetic group 3C.2a (226 viruses) or to the 
related subgroup 3C.2a1 (14), whereas 17 (7%) belonged to group 3C.3a.  
o Genetic group 3C.2a includes the A/Hong Kong/4801/2014 reference virus 
representing the A(H3N2) component of the 2017-2018 Northern 
Hemisphere influenza vaccines. 
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Background 
 Each season, CDC studies how well flu vaccines work by collecting data through the 
U.S. VE network of five sites across the United States. 
 Flu vaccine effectiveness can vary each year based on a number of factors, 
including the match between vaccine viruses and circulating viruses, what viruses 
are circulating, and the age and immune factors of the person being vaccinated.  
 CDC will continue to publish influenza laboratory and disease surveillance data 
weekly in FluView. 
 Updated VE estimates will be provided as warranted and final VE estimates will be 
published after the season ends. Final season VE estimates may differ from the 
interim estimates, and may be a little lower than the interim estimates.  
Vaccine Effectiveness, General 
 While vaccine effectiveness can vary, a study that pooled influenza vaccine 
effectiveness estimates from 2007 to 2015 by virus type and subtype found that: 
o Multi-year pooled vaccine effectiveness against influenza B viruses was 54%;  
o Multi-year pooled vaccine effectiveness against influenza A(H1N1)pdm09 
viruses was 61%;  
o Multi-year pooled vaccine effectiveness against H3N2 viruses was 33%. 
o Belongia EA, Simpson, MD, King JF, Sundaran ME, Kelley NS, 
Osterholm MT, McLean HQ. Variable influenza vaccine effectiveness by 
subtype: a systematic review and meta-analysis of test-negative 
design studies. Lancet Infect Dis. 2016; 16(8):942-51. 
 It is important to note that during seasons when the majority of circulating viruses 
are very different from a vaccine virus, vaccine effectiveness can be further 
reduced. 
 Two types of genetic changes can impact the similarity between a vaccine virus and 
circulating seasonal viruses. 
1. Influenza viruses constantly undergo small genetic changes. These genetic 
changes can sometimes result in antigenic changes. This is called “antigenic 
drift.” (Circulating viruses “drift” away from what is included in the vaccine.)  
 For more information on antigenic changes, see CDC’s Antigenic 
Characterization page at 
https://www.cdc.gov/flu/professionals/laboratory/antigenic.htm.  
2. Another type of change that can happen is that genetic changes occur when 
influenza viruses are grown in eggs, which is required for most U.S. flu 
vaccines.  
 These genetic changes (called “egg-adapted” changes) may have 
antigenic (or immunogenic) implications that may impact how well the 
vaccine works.  
 Egg-adapted changes that are associated with antigenic changes 
occur more often in H3N2 viruses.  
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 The lower vaccine effectiveness seen against H3N2 viruses during seasons when no 
antigenic drift has occurred may, in part, be caused by egg-adapted changes. 
 Most U.S. flu vaccines are produced using egg-based technology. 
 There are two flu vaccines in the United States that are not grown in eggs: 
recombinant influenza vaccine (Flublok) and cell-grown influenza vaccine 
(Flucelvax).  
o Recombinant vaccine is made by growing a certain protein from a 
naturally occurring (“wild type”) recommended vaccine virus in insect 
cells. 
o This season, Flucelvax is being made using a cell-grown H3N2 candidate 
vaccine virus for the first time.  
o Previously Flucelvax had been produced using cell-based technology but 
with candidate vaccine viruses isolated in eggs per FDA regulatory 
requirements.  
o On August 31, 2016, FDA approved the use of cell-isolated candidate 
vaccine viruses in the production of Flucelvax, the only licensed cell-based 
flu vaccine in the United States. 
 For recombinant and cell-grown vaccines, the H3N2 components are genetically 
more similar to circulating H3N2 viruses than the egg-adapted viruses 
recommended for egg-based manufacturing. 
 At this time there is insufficient data to determine whether cell-based or 
recombinant vaccine are more effective than egg-based vaccine. 
 Additional data is needed (including vaccine effectiveness data) before policy 
decisions on this topic could be considered. 
 
Flu & Sepsis 
 Flu infection can be associated with sepsis, even in otherwise healthy people, and 
that is a life-threatening condition.  
 CDC has received reports from some state health departments of flu deaths 
associated with sepsis this season.  
 A recent CDC study found that 30% of pediatric death reports included sepsis listed 
as a complication. 
 More information about sepsis can be found at 
https://www.cdc.gov/sepsis/index.html 
 
Vaccine Availability 
 Manufacturers report having shipped more than 154.7 million doses of flu vaccine 
as of February 9, 2018. 
 The total projected supply of vaccine in the United States this season is between 
151 million and 166 million doses of flu vaccine. About 119 million doses will be 
quadrivalent vaccine. 
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For Patients: 
CDC continues to recommend flu vaccination as the first line of defense against the flu. 
While some individual providers may be running low on flu vaccine at this point in the 
season, flu vaccine is available from a variety of providers throughout the country. Call 
your doctor, or use the flu vaccine finder to find where vaccine is available in your 
community.  
 
For Providers: 
Flu vaccine is available, but providers may not be able to get every brand and/or 
presentation, and they may have to purchase from a different source.  Providers 
interested in purchasing vaccine should check the influenza vaccine tracking availability 
system (IVATS) available at:  https://www.izsummitpartners.org/ivats/. 
 
Antiviral Supply Update 
 
 CDC is in regular contact with influenza antiviral manufacturers regarding supply 
and other issues. 
 Some manufacturers are reporting delays in filling orders and CDC is aware of spot 
shortages of antiviral drugs specifically for oseltamivir suspension and generic 
oseltamivir capsules in some places experiencing high influenza activity.  
 CDC is working with manufacturers, distributors, pharmacies, and pharmacy benefit 
managers to understand and address existing gaps in the market, including 
increasing access to brand name influenza antiviral medications, particularly for 
oseltamivir, in areas where there may be spot shortages of the generic version of 
the drug. 
 In response to high influenza activity this season and the high volume of influenza 
antiviral prescriptions dispensed, Genentech (i.e., the manufacturer of Tamiflu®, 
the brand name version of oseltamivir) has taken additional actions to increase 
patient access to product. 
o See Press release: https://www.gene.com/media/statements/ps_020518.   
 Additionally, major pharmacy benefit managers, including Express Scripts and 
OptumRX, have made Tamiflu® capsules and suspension preferred on their 
formularies (single source brand/preferred brand). A formulary is a list of drugs 
covered by an insurance company. So this move means that some insurance 
companies will now cover brand name oseltamivir (i.e., Tamiflu®), and it will allow 
for the drug to be covered at the lowest cost for a brand name drug (as determined 
by individual insurance companies). 
 In addition, some insurance company prescription plans are allowing the brand 
name product to be processed as generic, if the generic version of the drug is not 
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available. This means that they will cover Tamiflu® for the same copay as generic 
brands of oseltamivir, if the generic version is not available.  
 People seeking influenza antiviral medications, such as oseltamivir, are encouraged 
to check with their pharmacy or insurance company if they have additional 
questions on individual drug coverage. 
 Visit CDC’s antiviral supply page for the latest updates at 
https://www.cdc.gov/flu/professionals/antivirals/supply.htm.  
Additional Considerations: 
 Pharmacists should consider compounding oseltamivir suspension by using 
oseltamivir 75 mg capsules, if suspension is not readily available for patients that 
need it. 
 Pharmacies and others attempting to make bulk purchases of influenza antiviral 
drugs may need to call more than one distributor or manufacturer to locate 
medications available for purchase in the short term. CDC has updated its antiviral 
drug supply web page with manufacturer information for inquires related to 
antiviral purchases/availability. 
 Individual patients seeking to fill an influenza antiviral prescription may want to call 
ahead to make sure their pharmacy has product on the shelf to fill their 
prescription. It may be necessary to call more than one pharmacy to locate these 
medications. 
 Additional discounts may be available through some pharmaceutical providers.  
o See example news story: https://www.prnewswire.com/news-
releases/inside-rx-provides-savings-on-influenza-medications-
300593061.html.  
 Antiviral drugs work better the earlier you begin taking them so prompt action is 
important. 
 For people who have flu and are at high risk of serious flu complications, treatment 
with an antiviral drug can mean the difference between having a milder illness and 
having a very serious illness that could result in a hospital stay. 
 
Supply of Flu Tests & Testing Guidance 
 CDC has received reports of spot shortages of some influenza tests, including Rapid 
Influenza Diagnostic Tests (RIDTs) and Reverse Transcription-Polymerase Chain 
Reaction (RT-PCR). 
 These reports coincide with an ongoing intense and widespread seasonal influenza 
epidemic, during which spot shortage of flu vaccines and influenza antiviral 
medications also have been observed. 
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o RIDTs are tests that can identify the presence of influenza A and B viral 
nucleoprotein antigens in respiratory specimens, and display the result. 
o While RIDTs can be important for diagnosis and treatment, how well they work 
can vary dramatically based on a number of factors. 
o Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and other molecular 
assays can identify the presence of influenza viral RNA in respiratory specimens. 
• These test are generally much more reliable and are recommended by 
CDC for use on hospitalized patients. 
• According to CDC guidance, testing is not needed for all patients with signs and 
symptoms of influenza to make antiviral treatment decisions.  
• Once influenza activity has been documented in the community or geographic area, 
a clinical diagnosis of influenza can be made for outpatients with signs and 
symptoms consistent with suspected influenza, especially during periods of peak 
influenza activity in the community. 
• Guidance for Clinicians on the Use of RT-PCR and Other Molecular Assays for 
Diagnosis of Influenza Virus Infection is available at 
https://www.cdc.gov/flu/professionals/diagnosis/molecular-assays.htm . 
• Guidance on the use of RIDTs is available at 
https://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm . 
 
Influenza Treatment: Antiviral Medications 
 Antiviral drugs are prescription medicines (pills, liquid or an inhaled powder) and 
are not available over the counter.  
 Influenza antiviral drugs are the only drugs approved to treat influenza infection. 
 Antiviral drugs are different from antibiotics. Antiviral drugs fight viruses (like flu 
viruses) in your body; antibiotics fight infections in your body that are caused by 
bacteria.  
 Antiviral drugs can make flu illness milder and shorten the time you are sick.  
 There also are data showing that antiviral drugs may prevent serious flu 
complications such as pneumonia and hospitalizations in outpatients, and reduce 
mortality and length of stay in hospitalized patients.  
o For example, in 2015, a CDC study found that early treatment of flu-
hospitalized people 65 and older with flu antiviral medications cut the 
duration of their hospital stay and reduced their risk of needing extended 
care after discharge.  
o This study entitled “Impact of Prompt Influenza Antiviral Treatment on 
Extended Care Needs After Influenza Hospitalization Among Community-
Dwelling Older Adults” by Sandra Chaves et al. is available from the Clinical 
Infectious Diseases journal website at 
http://cid.oxfordjournals.org/content/early/2015/09/01/cid.civ733 .  
 Antiviral drugs work best when started within two days of symptoms first 
appearing, but there are data to suggest they can still be beneficial in very ill 
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patients even up to five days after getting sick. This would be especially important 
for a person who is at high risk of serious flu complications and who is very sick.  
 Three FDA-approved influenza antiviral drugs are recommended for use in the 
United States during the 2017-2018 influenza season: oseltamivir (Tamiflu® and 
generic formulations), zanamivir (Relenza®), and peramivir (Rapivab®). Generic 
formulations of oseltamivir became available commercially last season. 
 Antiviral drugs are not a substitute for getting a flu vaccine. The flu vaccine is the 
best way modern medicine currently has to prevent this potentially serious disease.  
 See Influenza Antiviral Medications: Summary for Clinicians on the CDC web site for 
additional information.  
 
Antiviral Side Effects Summary 
 With all medications there are reported side effects: 
 
Oral oseltamivir 
 This medication can be used for treatment of people  of all ages 
 Adverse reactions to oseltamivir include nausea, vomiting and headache. 
 There have also been some post-marketing reports of serious skin reactions and 
sporadic, transient neuropsychiatric events. 
 
Inhaled zanamivir 
 This drug can be used for treatment in those 7 years and older; however it isn’t 
recommended for use in people with underlying respiratory diseases (e.g., asthma, 
COPD), nor is it recommended for patients hospitalized with influenza 
 Zanamivir can be used for chemo-prophylaxis of those 5 years and older; however 
they shouldn’t use it if they have they have underlying respiratory diseases (e.g., 
asthma, COPD) 
 Allergic reactions have been reported to throat or facial swelling and a skin rash. 
 Some adverse reactions to zanamivir include bronchospasm, especially in the 
setting of underlying airways disease; sinusitis, dizziness, and ear, nose and throat 
infections. 
 There were some post-marketing reports of serious skin reactions and sporadic, 
transient neuropsychiatric events 
 
Intravenous peramivir 
 This drug can be used for treatment of those 2 years and older 
 Some adverse reactions to peramivir include diarrhea. 
 There were some post-marketing reports of serious skin reactions and sporadic, 
transient neuropsychiatric events 
 
For more information on safety, effectiveness and dosing for oral oseltamivir, inhaled 
zanamivir, and intravenous peramivir, visit the Food and Drugs Administration (FDA) 
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website https://www.fda.gov/Drugs/DrugSafety/ and/or consult the product package 
inserts. 
 
Communications Activities 
 On December 27, 2017, CDC issued a Health Advisory 
(https://emergency.cdc.gov/han/han00409.asp ) through the Health Alert Network, 
providing notice about 1) increased influenza A(H3N2) activity and its clinical 
implications, 2) a summary of influenza antiviral drug treatment recommendations, 
3) an update about approved treatment drugs and supply this season, and 4) 
background information for patients about influenza treatment.  
 The transcript for a January 12, 2018, is available at 
https://www.cdc.gov/media/releases/2018/t0112-widespread-flu-activity.html.  
 The video of a January 16, 2017, Public Health Grand Rounds on the influenza is 
available at https://www.cdc.gov/cdcgrandrounds/archives/2018/January2018.htm. 
 A transcript for a telebriefing held on January 26, 2018 is available at 
https://www.cdc.gov/media/releases/2018/t0126-flu-update-activity.html.  
 On Friday, February 2, 2018, a telebriefing was held. A transcript will be available 
at https://www.cdc.gov/media/releases/2018/t0202-flu-update-activity.html.  
 On Friday, February 9, 2018, a telebriefing was held. A transcript will be available 
at https://www.cdc.gov/media/releases/2018/t0209-flu-update-activity.html.  
 On Monday, February 12 a study on flu-related pediatric deaths appeared in the 
journal Pediatrics. The study: “Influenza-Associated Pediatric Deaths in the United 
States, 2010–2016” is available at 
http://pediatrics.aappublications.org/content/early/2018/02/09/peds.2017-2918.  
 On Thursday, February 15, HHS Secretary Alex Azar, joined by Acting CDC Director 
Anne Schuchat and others, held a press briefing to update the American public on 
the current state of influenza activity in the United States. Video of the briefing is 
available on the HHS YouTube page at 
https://www.youtube.com/watch?v=OeNyLGlNryA.   
 Also on Thursday, February 15, two influenza-related reports appeared in the 
Morbidity and Mortality Weekly Report (MMWR): “Interim Estimates of 2017-18 
Seasonal Influenza Vaccine Effectiveness – United States, February 2018” and 
“Update: Influenza Activity — United States, October 1, 2017–February 3, 2018” 
 
